United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BlackRock Science & Technology

Altria

Despite recent declines, the Dividend Harvesting Portfolio remains profitable, generating $1,908.79 in forward dividend income with a 23.38% return on invested capital. I believe the Fed's rate cuts are misplaced, and lower rates are needed to reduce housing costs and further curb inflation. I am bullish on 2025, expecting the portfolio to generate between $2,500-3,000 in dividend income, driven by reinvestments and weekly allocations.

Dividend Harvesting Portfolio Week 199: $19,900 Allocated, $1,908.79 In Projected Dividends

Medtronic

Realty Income Corp

Schwab US Dividend Equity ETF

You can pat yourself on the back if you're thinking of loading up your portfolio with dividend-paying stocks -- because they're surprisingly strong wealth builders. (If you weren't thinking of doing so, you can start now!

4 Dividend Stocks to Double Up on Right Now

High-yield dividend stocks often catch investors' attention -- and for good reason. When established companies maintain larger-than-average dividend payments, they can provide both substantial current income and the potential for long-term appreciation.

Better Income Stock: Pfizer or Altria Group?

Brookfield Corp

Costco

NVIDIA

Raytheon Technologies

I'm not a fan of New Year's Eve or market predictions. To shift the focus, I asked followers to select a single stock for a 10-year investment horizon. The responses were intriguing, ranging from a defensive giant to a high-growth sector leader. I analyzed each pick, considering their long-term prospects and potential for outperformance. Whether facing economic uncertainty or market volatility, these companies possess the qualities, I believe, are crucial for long-term investment success.

If You Could Only Buy One: 5 Top Dividend Stocks For The Next 10 Years

Pfizer hosted a discussion with sell-side analysts to provide an update on one of the vaccine pipeline items – a second-generation Clostridioides difficile (C. diff) vaccine effort in Phase 2.

Pfizer's Progress on C. diff Vaccine and Pneumococcal Shot Wins Analyst Conviction

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Pfizer (PFE) Stock?

Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

Johnson & Johnson

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Enterprise Products Partners

If you haven't finished your Christmas shopping yet, you're rapidly running out of time. I suspect many people have already purchased most of the gifts they'll give but might still have a few remaining.

Stocking Stuffers for Income Investors: 3 Ultra-High-Yield Dividend Stocks to Buy Before the End of 2024

Pfizer's stock has underperformed, but management's focus on R&D and cost efficiencies should boost margins and free cash flow, supporting a Buy rating. Despite political headwinds, PFE's valuation at 9x 2025 EPS and a 6.5% dividend yield make it attractive for long-term investors. Management's 2025 guidance indicates flat sales but improved profitability, with gross margins expected to reach the upper 70s, enhancing shareholder value and supporting its strong dividend payouts.

Pfizer's 2025 'Boring' Outlook Had A Nice Surprise That Was Overlooked

Amid a fall season characterized by restive shareholders seeking an activist bid to unseat senior management and change the trajectory of the company, Pfizer (PFE 2.29%) is communicating that everything is under control. Per its updated forecast for its 2024 and 2025 fiscal years on Dec. 17, the overarching message is that the pharma will continue to seek to control its costs while bolstering its portfolio of medicines as usual.

Pfizer Just Reassured Investors, but Is the Stock a Buy?

AbbVie

Stock market investors have plenty of reasons to celebrate as 2024 comes to a close. The S&P 500 index set multiple new record highs during the year, delivering a spectacular 25% return year to date amid a resilient economy and strong corporate earnings.

2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off

Abbott Labs

Amazon

American Express

CrowdStrike

Etsy

Palantir Technologies

Viking Therapeutics

Vertex Pharmaceuticals

It's that time of year again. I'm not referring to buying gifts and preparing holiday meals -- although that may be part of your agenda too.

My Top 10 Stocks to Buy for 2025

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test.i The indication was approved based on a statistically significant and clinically meaningful improvem.

U.S. FDA Approves Pfizer's BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer

Pfizer (PFE) concluded the recent trading session at $25.77, signifying a -0.46% move from its prior day's close.

Why Pfizer (PFE) Dipped More Than Broader Market Today

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:30 a.m. EST on Tuesday, February 4, 2025. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Fourth Quarter and Full Year 2024 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.c.

Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts

Shares of Pfizer (PFE -2.04%) recently marched higher in response to a dividend payout raise and a forward-looking presentation. Management confirmed the annual revenue and earnings outlook it provided in October and issued guidance for the year ahead.

Pfizer Could Soar to $36 Per Share, According to a Wall Street Analyst. Is It a Buy at Around $26?

Grindr Inc

WEST HOLLYWOOD, Calif.--(BUSINESS WIRE)--From December 22 to January 2, people on Grindr across the globe can experience Roam, a popular new feature, free of charge.

Roam For the Holidays: Grindr Offers Free Access to Their Popular Travel Feature

Pfizer Inc.'s technical indicators have shifted from bullish to bearish, with the stock now trading below its 30-week EMA and showing bearish momentum. Volume analysis indicates recent institutional selling, and relative strength has deteriorated, underperforming the S&P 500 since July 2024. Pfizer stock is in a consolidation phase, potentially setting up for a bull run if it can recapture its 30-week EMA and show bullish volume.

Pfizer Momentum Shift Makes Me Less Bullish (Technical Analysis)

Pfizer projects total revenues between $61.0 and $64.0 billion with EPS in the range of $2.80 to $3.00.

Pfizer Stock Up 5% as 2025 Guidance Meets Investor Expectations

Pfizer stock (NYSE: PFE) was up 5% on Tuesday, December 17, after the company announced an optimistic outlook for 2025. The company expects its revenue to be in the range of $61 billion to $64 billion, and its adjusted earnings to be in the range of $2.80 and $3.00 per share.

Is Pfizer Stock Undervalued?

Pfizer stock is setting up for a wild ride in 2025 as it faces off with an activist and Robert F. Kennedy Jr. as the possible HHS lead.

Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy

Annaly Capital

Arguably the greatest aspect of putting your money to work on Wall Street is that there's no one-size-fits-all strategy to generate wealth. With thousands of publicly traded companies and exchange-traded funds (ETFs) to choose from, there are bound to be securities that can help you meet your investment goals.

3 of the Safest Ultra-High-Yield Dividend Stocks to Buy in 2025

Pfizer (NYSE: PFE) shares rose nearly 3% to $25.98 in premarket trading on December 17 after the pharmaceutical giant released its 2025 financial guidance.

Here's why Pfizer (PFE) stock is surging

Shares of Pfizer Inc.  PFE are making a large move higher Tuesday. But the stock has run into resistance.

News for Pfizer Stock (PFE)